John E. Kao Sells 27,535 Shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John E. Kao sold 27,535 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $16.89, for a total transaction of $465,066.15. Following the completion of the transaction, the chief executive officer now directly owns 4,991,717 shares in the company, valued at approximately $84,310,100.13. The trade was a 0.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Alignment Healthcare Stock Up 2.5 %

Shares of NASDAQ:ALHC opened at $17.61 on Friday. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 1.82. The stock has a market capitalization of $3.38 billion, a P/E ratio of -22.87 and a beta of 1.49. Alignment Healthcare, Inc. has a 12-month low of $4.46 and a 12-month high of $17.76. The stock’s 50-day moving average price is $14.90 and its 200-day moving average price is $12.69.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ALHC shares. Stifel Nicolaus raised their price target on Alignment Healthcare from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Barclays raised their price target on Alignment Healthcare from $8.00 to $9.00 and gave the company an “underweight” rating in a research report on Friday, February 28th. William Blair restated an “outperform” rating on shares of Alignment Healthcare in a research report on Friday, February 28th. Stephens restated an “overweight” rating and set a $17.00 price target on shares of Alignment Healthcare in a research report on Monday, February 24th. Finally, Piper Sandler raised their price target on Alignment Healthcare from $14.00 to $21.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Alignment Healthcare presently has an average rating of “Moderate Buy” and an average target price of $14.83.

Institutional Trading of Alignment Healthcare

Several large investors have recently modified their holdings of the business. Mackenzie Financial Corp grew its stake in shares of Alignment Healthcare by 149.8% in the fourth quarter. Mackenzie Financial Corp now owns 85,175 shares of the company’s stock worth $958,000 after purchasing an additional 51,084 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Alignment Healthcare by 15.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 263,203 shares of the company’s stock worth $2,961,000 after purchasing an additional 36,151 shares during the last quarter. Voloridge Investment Management LLC bought a new stake in shares of Alignment Healthcare in the fourth quarter worth about $189,000. Squarepoint Ops LLC grew its stake in shares of Alignment Healthcare by 414.6% in the fourth quarter. Squarepoint Ops LLC now owns 198,309 shares of the company’s stock worth $2,231,000 after purchasing an additional 159,774 shares during the last quarter. Finally, Two Sigma Investments LP bought a new stake in shares of Alignment Healthcare in the fourth quarter worth about $258,000. 86.19% of the stock is owned by institutional investors.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.